Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus sonrotoclax in treatment-naive CLL/SLL with TP53 risk stratification
ChiCTR2600131015Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and sonrotoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by West China Hospital of Sichuan University. Primary endpoint: Proportion of patients with complete remission. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zanubrutinibsonrotoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2600131015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131015.